Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved ...

Experts explore HER2 mutations and the critical role of comprehensive molecular profiling in optimizing treatment for ...

Ticiana Leal, MD, Winship Cancer Institutes, explains the importance of biomarker testing and multidisciplinary conversations while caring for patients with early-stage non–small cell lung cancer ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

A 62-year-old woman with stage IIIA lung cancer faces complex diagnostic and treatment decisions, highlighting the importance ...

—A team of researchers in Tokyo recently took on the challenge of attempting to determine whether comprehensive genomic profiling has clinical utility in a large cohort of patients with non-small cell ...

Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...

FORT MYERS, Fla., May 22, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology testing services, today announced the commercial launch of c-MET CDx for NSCLC, its ...

FORT MYERS, Fla. - NeoGenomics, Inc. (NASDAQ: NEO), a provider of cancer testing services with annual revenue of $672 million and healthy liquidity metrics, has introduced a new diagnostic assay, ...

The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.